Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer
© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC..
BACKGROUND: NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment.
AIMS: This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach.
METHODS: Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Following that, the Drug-Gene Interaction Database was used to find possible drugs that target important genes within two gene co-expression modules linked to non-small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug-gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs.
RESULTS: Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non-small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug-gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib.
CONCLUSION: Hence, there is a possibility of repurposing these drugs for the treatment of non-small-cell lung cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Cancer reports (Hoboken, N.J.) - 7(2024), 4 vom: 15. Apr., Seite e2031 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Adeyemo, Oluwatosin Maryam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug–gene interaction |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/cnr2.2031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370893794 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370893794 | ||
| 003 | DE-627 | ||
| 005 | 20240425233741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cnr2.2031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370893794 | ||
| 035 | |a (NLM)38600056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Adeyemo, Oluwatosin Maryam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Network-based identification of key proteins and repositioning of drugs for non-small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: NSCLC is a lethal cancer that is highly prevalent and accounts for 85% of cases of lung cancer. Conventional cancer treatments, such as chemotherapy and radiation, frequently exhibit limited efficacy and notable adverse reactions. Therefore, a drug repurposing method is proposed for effective NSCLC treatment | ||
| 520 | |a AIMS: This study aims to evaluate candidate drugs that are effective for NSCLC at the clinical level using a systems biology and network analysis approach | ||
| 520 | |a METHODS: Differentially expressed genes in transcriptomics data were identified using the systems biology and network analysis approaches. A network of gene co-expression was developed with the aim of detecting two modules of gene co-expression. Following that, the Drug-Gene Interaction Database was used to find possible drugs that target important genes within two gene co-expression modules linked to non-small cell lung cancer (NSCLC). The use of Cytoscape facilitated the creation of a drug-gene interaction network. Finally, gene set enrichment analysis was done to validate candidate drugs | ||
| 520 | |a RESULTS: Unlike previous research on repositioning drugs for NSCLC, which uses a gene co-expression network, this project is the first to research both gene co-expression and co-occurrence networks. And the co-occurrence network also accounts for differentially expressed genes in cancer cells and their adjacent normal cells. For effective management of non-small cell lung cancer (NSCLC), drugs that show higher gene regulation and gene affinity within the drug-gene interaction network are thought to be important. According to the discourse, NSCLC genes have a lot of control over medicines like vincristine, fluorouracil, methotrexate, clotrimazole, etoposide, tamoxifen, sorafenib, doxorubicin, and pazopanib | ||
| 520 | |a CONCLUSION: Hence, there is a possibility of repurposing these drugs for the treatment of non-small-cell lung cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a drug–gene interaction | |
| 650 | 4 | |a network analysis | |
| 650 | 4 | |a non‐small cell lung cancer (NSCLC) | |
| 650 | 4 | |a therapeutics | |
| 700 | 1 | |a Ashimiyu-Abdusalam, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Adewunmi, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Ayano, Temitope Ayanfunke |e verfasserin |4 aut | |
| 700 | 1 | |a Sohaib, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Salam, Reem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer reports (Hoboken, N.J.) |d 2018 |g 7(2024), 4 vom: 15. Apr., Seite e2031 |w (DE-627)NLM309522617 |x 2573-8348 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:e2031 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cnr2.2031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 4 |b 15 |c 04 |h e2031 | ||